1. Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease
- Author
-
Esther Garcia-Planella, Federico Bertoletti, Marta Fortuny, Anna Calm, Cristina Roig, Jordi Gordillo, Eugeni Domènech, Fiorella Cañete, Laura González-González, C González-Muñoza, M Calafat, Antonio Mombiela, Míriam Mañosa, and Marta Teller-Martín
- Subjects
Aging ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Short Communication ,Population ,Disease ,Inflammatory bowel disease ,03 medical and health sciences ,0302 clinical medicine ,Elderly ,Risk Factors ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Risk factor ,education ,Thiopurines ,Aged ,education.field_of_study ,business.industry ,SARS-CoV-2 ,Incidence (epidemiology) ,COVID-19 ,medicine.disease ,Inflammatory Bowel Diseases ,Immunosuppressants ,Concomitant ,Geriatrics and Gerontology ,business ,030217 neurology & neurosurgery ,Immunosuppressive Agents - Abstract
Background Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate. Aim To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation to the use of IMS. Methods IBD patients over 65 years of age were selected and grouped in terms of IMS use. Confirmed COVID-19, adherence to IST, comorbidities and concomitant non-IBD-related treatments between 1st of March 2020 to 1st of March 2021 were recorded. Results Out of 418 patients included, 89 (21.3%) were on IMS. Thirty-two patients (7.7%) had COVID-19, 7 of whom were on IMS (7.6% not on IMS vs. 7.9% on IMS; P = 0.933) and 7 (22%) patients died. Conclusions Incidence of COVID-19 among elderly IBD patients was similar to that reported in the background population, regardless of the use of IMS.
- Published
- 2021